^
Association details:
| Biomarker: | CLDN18.2 expression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | satricabtagene autoleucel (CT041) (CLDN18.2-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
Published date:
09/09/2023
Excerpt:
Here, we reported two metastatic pancreatic cancer patients administrated with Claudin 18.2 (CLDN 18.2) CART therapy after the failure of standard therapy...In case 1, with CLDN 18.2 expression of 2+, 70%, 250 × 106 cells were infused after lymphodepletion....Partial response (PR) was achieved according to RECIST v1.1, with great shrinkage of lung metastasis....The tumor is still under well control until the last follow-up on July 18, 2023.
DOI:
10.1186/s13045-023-01491-9
